Colrain Capital LLC Has $8.03 Million Holdings in Bristol Myers Squibb Company $BMY

Colrain Capital LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 43.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 178,025 shares of the biopharmaceutical company’s stock after acquiring an additional 54,025 shares during the quarter. Bristol Myers Squibb makes up about 4.6% of Colrain Capital LLC’s investment portfolio, making the stock its 9th biggest position. Colrain Capital LLC’s holdings in Bristol Myers Squibb were worth $8,029,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. NEOS Investment Management LLC lifted its holdings in Bristol Myers Squibb by 13.2% in the 3rd quarter. NEOS Investment Management LLC now owns 306,115 shares of the biopharmaceutical company’s stock worth $13,806,000 after purchasing an additional 35,641 shares in the last quarter. Arvest Bank Trust Division raised its position in shares of Bristol Myers Squibb by 7.1% during the third quarter. Arvest Bank Trust Division now owns 12,178 shares of the biopharmaceutical company’s stock valued at $549,000 after buying an additional 804 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Bristol Myers Squibb by 30.1% in the third quarter. GSA Capital Partners LLP now owns 61,578 shares of the biopharmaceutical company’s stock worth $2,777,000 after buying an additional 14,260 shares in the last quarter. Founders Financial Alliance LLC boosted its position in shares of Bristol Myers Squibb by 17.5% during the third quarter. Founders Financial Alliance LLC now owns 9,452 shares of the biopharmaceutical company’s stock worth $426,000 after acquiring an additional 1,407 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in Bristol Myers Squibb by 59.9% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 3,719,987 shares of the biopharmaceutical company’s stock valued at $167,771,000 after acquiring an additional 1,393,646 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.64 on Tuesday. The business’s 50 day moving average price is $55.50 and its 200-day moving average price is $49.61. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a market cap of $123.49 billion, a P/E ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the business earned $1.67 earnings per share. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Piper Sandler restated an “overweight” rating and set a $66.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Leerink Partners upped their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.